Weight loss with semaglutide in Danish adults: user traits, treatment hopes, and reported results

The authors declare no conflict of interest. Anton Pottegård reports participation in research projects funded by Alcon, Almirall, Astellas, AstraZeneca, Boehringer‐Ingelheim, Novo Nordisk, Servier and LEO Pharma (all regulator‐mandated phase IV‐studies), and an unrestricted research grant from Novo Nordisk, all with funds paid to the institution where he was employed (no personal fees) and with no relation to the work reported in this article. Reimar W. Thomsen reports that he has given presentations and lectures on medical research (both with and without financial compensation) for various companies, including AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Sanofi. He reports no other personal conflicts of interest; however, the Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital receives funding for other studies from companies in the form of research grants to (and administered by) Aarhus University. None of these studies have any relation to the current study.